These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 12108893)
1. Docetaxel in the management of advanced or metastatic urothelial tract cancer. Logothetis C; Millikan R Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):107-11. PubMed ID: 12108893 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Dreicer R; Manola J; Schneider DJ; Schwerkoske JF; George CS; Roth BJ; Wilding G; Cancer; 2003 Jun; 97(11):2743-7. PubMed ID: 12767086 [TBL] [Abstract][Full Text] [Related]
3. Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine. Bellmunt J; Albanell J; Paz-Ares L; Climent MA; González-Larriba JL; Carles J; de la Cruz JJ; Guillem V; Díaz-Rubio E; Cortés-Funes H; Baselga J; Cancer; 2002 Aug; 95(4):751-7. PubMed ID: 12209718 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and docetaxel as first-line treatment for advanced urothelial carcinoma: a phase II study. Ardavanis A; Tryfonopoulos D; Alexopoulos A; Kandylis C; Lainakis G; Rigatos G Br J Cancer; 2005 Feb; 92(4):645-50. PubMed ID: 15685232 [TBL] [Abstract][Full Text] [Related]
5. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068 [TBL] [Abstract][Full Text] [Related]
6. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial. Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001 [TBL] [Abstract][Full Text] [Related]
7. Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancer. Green MR Semin Oncol; 2002 Jun; 29(3 Suppl 12):17-21. PubMed ID: 12170447 [TBL] [Abstract][Full Text] [Related]
8. Current and future perspectives in advanced bladder cancer: is there a new standard? von der Maase H Semin Oncol; 2002 Feb; 29(1 Suppl 3):3-14. PubMed ID: 11894002 [TBL] [Abstract][Full Text] [Related]
9. The current status of docetaxel for metastatic breast cancer. Esteva FJ Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894 [TBL] [Abstract][Full Text] [Related]
10. A phase II study of gemcitabine and docetaxel therapy in patients with advanced urothelial carcinoma. Gitlitz BJ; Baker C; Chapman Y; Allen HJ; Bosserman LD; Patel R; Sanchez JD; Shapiro RM; Figlin RA Cancer; 2003 Nov; 98(9):1863-9. PubMed ID: 14584068 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Kelly WK; Scher HI; Bajorin DF J Clin Oncol; 1997 May; 15(5):1853-7. PubMed ID: 9164195 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel/gemcitabine: salvage chemotherapy in anthracycline-pretreated patients with advanced breast cancer. Georgoulias VA Oncology (Williston Park); 2001 Feb; 15(2 Suppl 3):18-24. PubMed ID: 11252884 [TBL] [Abstract][Full Text] [Related]
13. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract. Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526 [TBL] [Abstract][Full Text] [Related]
14. Docetaxel for locally advanced or metastatic non-small-cell lung cancer. Current data and future directions as front-line therapy. Khuri FR Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):53-62. PubMed ID: 12108898 [TBL] [Abstract][Full Text] [Related]
15. Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. Krege S; Rembrink V; Börgermann C; Otto T; Rübben H J Urol; 2001 Jan; 165(1):67-71. PubMed ID: 11125366 [TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial. Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298 [TBL] [Abstract][Full Text] [Related]
17. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. Bellmunt J; Guillem V; Paz-Ares L; González-Larriba JL; Carles J; Batiste-Alentorn E; Sáenz A; López-Brea M; Font A; Nogué M; Bastús R; Climent MA; de la Cruz JJ; Albanell J; Banús JM; Gallardo E; Diaz-Rubio E; Cortés-Funes H; Baselga J J Clin Oncol; 2000 Sep; 18(18):3247-55. PubMed ID: 10986057 [TBL] [Abstract][Full Text] [Related]
18. Combination of gemcitabine and paclitaxel is a favorable option for patients with advanced or metastatic urothelial carcinoma previously treated with cisplatin-based chemotherapy. Ikeda M; Matsumoto K; Tabata K; Minamida S; Fujita T; Satoh T; Iwamura M; Baba S Jpn J Clin Oncol; 2011 Oct; 41(10):1214-20. PubMed ID: 21903707 [TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients. de Wit R; Kruit WH; Stoter G; de Boer M; Kerger J; Verweij J Br J Cancer; 1998 Nov; 78(10):1342-5. PubMed ID: 9823976 [TBL] [Abstract][Full Text] [Related]
20. Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium. Meluch AA; Burris HS; Greco FA; Hainsworth JD Eur J Cancer; 2000 Jul; 36 Suppl 2():30-3. PubMed ID: 10908846 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]